PMID: 11915663Mar 28, 2002Paper

Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma

Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
Harald HolteGeir E Tjønnfjord

Abstract

Clinical studies over the last 20 years using more intensive cytostatic regimens show improved results in children and adolescents with aggressive non-Hodgkin's lymphoma and in adult patients specifically with Burkitt's lymphoma. We present a retrospective analysis of the use of the Berlin-Frankfurt-Munster (BFM) regimen for patients older than 15 years from three Norwegian university hospitals during the 1992-99 period. Survival data for 24 patients 15-69 years old with Burkitt's lymphoma/B-cell acute lymphoblastic leukaemia (B-ALL) show an estimated overall five year survival of 70% (75% for Burkitt's lymphoma only). Eight of ten adolescent patients 15-20 years old with other aggressive lymphomas were alive and disease free at last follow-up. All nine patients given the regimen after failure of prior therapy died of lymphoma within six years. The BFM regimen yields impressive results as the primary treatment of adolescent and adult patients with Burkitt's lymphomas/B-ALL.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

The New England Journal of Medicine
Kieron DunleavyWyndham H Wilson
Expert Opinion on Biological Therapy
Eric Jacobsen, A S Lacasce
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
Alan DavidsonHeinz Rode
© 2022 Meta ULC. All rights reserved